Multiple sclerosis BTK inhibitor CNS-penetrant FDA approval with progressive MS treatment research
RegulatoryBusiness Wire

Sanofi Receives FDA Approval for Tolebrutinib in Non-Relapsing Secondary Progressive MS

Sanofi announces FDA approval of tolebrutinib as the first BTK inhibitor approved for non-relapsing secondary progressive multiple sclerosis.

Sanofi today announced that the FDA has approved tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS), marking the first BTK inhibitor approved for this form of MS. In the Phase 3 HERCULES trial, tolebrutinib significantly reduced the risk of 6-month confirmed disability progression by 31% compared to placebo. The approval addresses a significant unmet need in nrSPMS, where few effective treatments exist. Tolebrutinib's ability to cross the blood-brain barrier and act on CNS-resident immune cells represents a novel mechanism of action in MS treatment.

Original Source

Business Wire
Share:

Previous

Amgen Receives FDA Approval for Rocatinlimab in Moderate-to-Severe Atopic Dermatitis

Next

Bristol Myers Squibb Receives FDA Approval for Sotyktu in Psoriatic Arthritis